CollPlant Faces Nasdaq Delisting Risk as Share Price Dips Below $1
Event summary
- CollPlant Biotechnologies received a Nasdaq deficiency notice on March 23, 2026, due to its share price falling below $1.00 for 30 consecutive trading days.
- The company has 180 calendar days, until September 21, 2026, to regain compliance by achieving a closing bid price of at least $1.00 for 10 consecutive trading days.
- Failure to comply by September 21, 2026, could lead to a second 180-day compliance period requiring a reverse share split and meeting other initial listing standards.
- Delisting is possible if compliance is not achieved within the extended period(s).
The big picture
CollPlant's situation highlights the challenges faced by smaller biotech companies with limited capital and volatile share prices. The Nasdaq's minimum bid price requirement is a common hurdle, and the potential for delisting underscores the importance of maintaining investor confidence and demonstrating a clear path to profitability. The company's reliance on its partnership with AbbVie for revenue generation makes its future success heavily dependent on the continued success of that collaboration.
What we're watching
- Share Price Trajectory
- The company's ability to sustain a share price above $1.00 within the next six months will be critical, and will likely dictate investor sentiment and potential financing options.
- Reverse Split Probability
- The likelihood of CollPlant implementing a reverse share split to meet the compliance requirement will depend on investor appetite and the perceived long-term viability of the business.
- AbbVie Partnership
- The ongoing success and revenue generation from the partnership with AbbVie will be a key factor in CollPlant's ability to regain financial stability and investor confidence.
Related topics